🧬 Student Spotlight

Good morning everyone. Today I'll be presenting a literature review titled From Alpha-Synuclein Mutation to Targeted Therapy. We will be walking through 5 landmark papers to see how Parkinson's disease research has evolved over nearly 3 decades, from observing protein deposits under a microscope to engineering molecules that can target those same proteins in living systems. Parkinson's disease is characterized by the progressive loss of dopamine-producing neurons in the brain. A defining feature of affected neurons is the presence of Lewy bodies, abnormal protein. The central cause behind these structures is a protein called alpha-synuclein. Our goal today is to trace how scientists first identified alpha-synuclein's role in disease and eventually used that knowledge to design therapies. Our timeline begins in 1997 with 2 landmark studies. Spillantini and colleagues examined postmortem brain tissue and discovered that alpha-synuclein was the primary protein inside Lewy bodies. In the same exact year, Polymeropoulos and his team identified the A53T mutation in the SNCA gene within families affected by hereditary Parkinson's. Together, these papers established alpha-synuclein in Parkinson's pathology. Fast forward to 2022 and 2024. Once researchers knew alpha-synuclein was central to the disease, the focus shifted to uncovering the exact structural mechanisms causing its aggregation. Ahmed et al. introduced synthetic foldomers, or synthetic molecules designed to mimic protein structures that bind to specific regions of alpha-synuclein to disrupt aggregation. Dillman et al. built on this by developing 2D-FAST, a structural screening approach that produced compounds capable of protecting dopaminergic neurons. These 2 papers showed that protein aggregation could be actively engineered against. The most recent milestone comes from Doanh et al. In 2026, while previous These therapies showed promise in test tubes and worm models. Candidate SK-129 demonstrated that polymer technology can work in mammals. Crucially, SK-129 crossed the blood-brain barrier, protected dopaminergic neurons, and improved survival in A53T mouse models. It also blocked co-aggregation between alpha-synuclein tau, showing potential across multiple neurodegenerative pathways. To conclude, this literature review illustrates a complete scientific arc. In 1997, researchers answered what was accumulating in the brain and which gene was mutated. By the early 2020s, scientists mapped how the protein misfolds on a molecular level. And by 2026, those insights resulted in targeted candidates capable of preventing neurodegenerative diseases in mammalian models. However, as promising as candidates like SK-129 are, these findings represent an early step rather than a final cure. The next critical phase of research must address several key transition hurdles. First, researchers need to confirm long-term studies optimal dosing and toxicity profiles over extended periods. Second, because the A53T mutation represents only a fraction of Parkinson's cases, these therapies must be tested across border models, broader models of sporadic disease, or people who don't have the mutation. Most importantly, future studies need to prove that reducing visible protein aggregates. actually halts the loss of functional dopamine neurons in humans. Bridging this gap between stopping protein misfolding in laboratory models and safely altering disease progression in the human brain remains the ultimate challenge and the primary objective for the next generation of Parkinson's research. Thank you.